Indeed it was a doozy. That was during the white h
Post# of 72440
Not sure why he thinks our pipeline trumps theirs. They only had one drug but it was worth over $40B (the $21B mentioned was for half the sales).
I suppose it's possible a fully developed Brilacidin platform could be worth that. Kevetrin also has the potential to be larger. We're a long way from both though.
Let's focus on 1% of that success and get our market cap back to $400M in 2018. From there we can dream of $4B and beyond.
Go IPIX!